InflaRx

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees74

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees74

IFRX Key Statistics

Market cap

94.66M

Market cap94.66M

Price-Earnings ratio

-1.13

Price-Earnings ratio-1.13

Dividend yield

—

Dividend yield—

Average volume

829.45K

Average volume829.45K

High today

$1.42

High today$1.42

Low today

$1.18

Low today$1.18

Open price

$1.20

Open price$1.20

Volume

624.71K

Volume624.71K

52 Week high

$2.82

52 Week high$2.82

52 Week low

$0.7113

52 Week low$0.7113

IFRX News

Seeking Alpha 6d

InflaRx regains Nasdaq minimum bid price compliance

Healthcare InflaRx regains Nasdaq minimum bid price compliance Sep. 12, 2025 8:51 AM ET InflaRx N.V. (IFRX) Stock By: Soumendra Mukherjee, SA News Editor 5 Shar...

TipRanks 6d

InflaRx regains compliance with Nasdaq min bid price requirement

InflaRx (IFRX) announced that it has received a written notice, dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.